Month: September 2025

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive research-based biopharma experience gained over a long and successful career and currently serves as Immediate Past Chairman of the Biotechnology Innovation Organization’s (BIO) Board of Directors. Ted has consistently demonstrated exceptional judgment and leadership, and we look forward to his continued stewardship as...

Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex’s Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal disease, alongside Enlivex’s Vice Chairman and D. Boral’s Research Director.   The September 30 KOL webinar will explore recent breakthroughs in treatment approaches discussing the positive Phase IIa topline data from Enlivex’s Allocetra™ program in moderate-to-severe knee osteoarthritis (KOA) patients. Data demonstrated...

Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products; exploring additional direct-to-employer model to increase access and affordability for cash-paying patients in the USBasel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx® (secukinumab) the option to purchase it at a 55% discount off the list price. Cosentyx, Novartis top selling product in the US, is a biologic that is FDA-approved for the treatment of multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa and psoriatic arthritis. It has been studied...

Ruggedized, AI-Driven Edge Computing Platform for Military and Homeland Security Applications Rehovot, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in video and artificial intelligence (“AI”) – based edge computing technology, today announced the launch of Peridot Night, a situational awareness and terrain dominance solution designed to enhance visibility, safety, and operational decision-making across ground, aerial, and maritime platforms, as well as fixed locations. Peridot Night will be premiered at AUSA 2025 (Association of the United States Army), at Maris-Tech’s booth #2154, Hall B. Click here to schedule a demo. Powered by Maris’ Jupiter-AI edge computing platform, Peridot Night integrates three thermal and one full-HD day camera to deliver...

HSDT Solana Company’s Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors HSDT enters into agreement with the Solana Foundation to establish its collaboration and commit to joint initiatives This signifies HSDT’s commitment to building a long-lasting institution that accelerates the growth of Solana and being a powerful advocate for Solana’s development alongside the independent Solana Foundation and Solana Lab NEWTOWN, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“HSDT” or the “Company”) announced that, following receipt of approval from its Board of Directors, it has filed an amendment to its Certificate of Incorporation with the Delaware Secretary of State...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) —  Getty Images Holdings, Inc. (NYSE: GETY) (“Getty Images”) announced today that its indirect wholly owned subsidiary, Getty Images, Inc. (the “Issuer”), plans to offer, in a private offering, subject to market and other conditions, $628,400,000 aggregate principal amount of senior secured notes due 2030 (the “Notes”). The Notes will be senior secured obligations of the Issuer and will be jointly and severally guaranteed on a senior secured first lien basis by the same guarantors that provide guarantees for the Issuer’s outstanding senior secured notes due 2030 and its secured credit facility. The offering is being made in connection with the previously announced proposed merger (the “Merger”) with Shutterstock, Inc. (“Shutterstock”), to create a premier visual content company. An amount...

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modality of radiation therapy usedNEEDHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, presented subgroup analyses focused on the radiation regimen from the Company’s positive phase 3 clinical trial of CAN-2409 (aglatimagene besadenovec) in patients with intermediate-to-high-risk localized prostate cancer at the 2025 Annual Meeting of the American Society for Radiation...

Netanya, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today announced that it has received a new purchase order valued at approximately $100,000 from a leading military unit for its tactical headset systems and related communication accessories. This order marks another milestone in Silynxcom’s ongoing commitment to equipping elite military forces with advanced communication solutions. The Company’s tactical headsets, renowned for their combat-proven reliability, provide superior situational awareness, active hearing protection, and seamless integration with professional-grade ruggedized radios. These features ensure clear and precise communication in high-intensity operational environments,...

KETAFREE™ to provide innovative, preservative-free IV ketamine formulation, eliminating toxic preservatives, in keeping with current HHS priorities to eliminate toxic preservatives from foods and drugs Filing is based on FDA interaction and approval of Suitability Petition for NRx’s proposed strength of preservative-free ketamine This presentation of ketamine represents a reshoring of a strategically important drug to the US, in keeping with the Presidential Executive Order signed on May 5, 2025. Ketamine faces a current US drug shortage not expected to abate in the near future1 Current ketamine market estimated at $750 million and projected to reach $3.35 billion globally in 2034.2 NRx anticipates marketing KETAFREE™ for currently approved ketamine indications The Company has filed a citizen’s petition with the FDA to remove...